Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities (Q37836508)

24 August 2017

1 reference

title

Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities (English)

1 reference

24 August 2017

1 reference

3

Christian Blank

1 reference

24 August 2017

1

Axel Bex

1 reference

24 August 2017

James Larkin

2

1 reference

24 August 2017

publication date

1 June 2011

1 reference

24 August 2017

published in

Current Oncology Reports

1 reference

24 August 2017

volume

13

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

240-248

1 reference

24 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Estimates of the cancer incidence and mortality in Europe in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

2004 WHO classification of the renal tumors of the adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Long-term response in primary renal cancer to sequential antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Targeting the Met signaling pathway in renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Targeting the HGF/c-Met axis: state of play.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Germline SDHB mutations and familial renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Molecular pathology of chromophobe renal cell carcinoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Overexpression of KIT in chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Xp11 translocation renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Xp11 Translocation Renal Cell Carcinoma (RCC): Extended Immunohistochemical Profile Emphasizing Novel RCC Markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Metastatic Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Responding to Sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0159-Y

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors

21 January 2018

1 reference

12 December 2020

Sequential use of targeted agents in the treatment of renal cell carcinoma

1 reference

12 December 2020

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma

1 reference

12 December 2020

Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors

1 reference

12 December 2020

XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.

1 reference

12 December 2020

The role of radical nephrectomy in metastatic renal cell carcinoma

1 reference

12 December 2020

Collecting duct carcinoma of kidney

1 reference

12 December 2020

Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN

1 reference

12 December 2020

10.1007/S11912-011-0159-Y

Identifiers

DOI

1 reference

24 August 2017

1 reference